StockData

Medinotec Inc. (MDNC) stock analysis

MDNCOTCSurgical & Medical Instruments & ApparatusFiscal year ends February 28
Financials through Q2 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 9/30
$5.00+0.00 (0.00%)

Close on Oct 16, 2026Market cap $58.78MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance4Health4Dividend0

Mixed9 of 30 checks passed

Medinotec passes 9 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
4/6
Financial health
4/6
Dividend
0/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 17.9%, above the 10% that usually covers the cost of capital.

  • Low debt

    Debt is 0.0% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 114% a year over the last three fiscal years.

  • Interest well covered

    Operating income covers interest expense 21.8 times.

What to watch

  • Return on equity under 15%

    Return on equity was 11.1% over the last twelve months and averaged 8.0% over five years; we look for 15% on both.

  • Growing slower than the industry

    Revenue grew -10.9% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Gross margin slipping

    Gross margin was 49.6% over the last twelve months, against 54.8% a year earlier.

  • No dividend

    Medinotec has not paid a dividend in the last twelve months.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing 10%+ a year

    Revenue grew 114% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -10.9% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 11.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 49.6% over the last twelve months, against 54.8% a year earlier.

Past performance4/6

  • Return on equity under 15%

    Return on equity was 11.1% over the last twelve months and averaged 8.0% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 17.9%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Medinotec's return on equity of 11.1% is above the Surgical, Medical, and Dental Instruments and Supplies median of -31.3%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 5.8% over the last twelve months, against a 5-year average of -2.9%.

  • Net margin above the industry

    Medinotec's net margin of 5.8% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.

Financial health4/6

  • Low debt

    Debt is 0.0% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 75231% of total debt.

  • Interest well covered

    Operating income covers interest expense 21.8 times.

  • Short-term assets cover short-term debts

    Current assets are 6.74 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Medinotec has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Medinotec. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • EV/EBITDA at month end
  • Own 5-year median 43.3
  • Surgical, Medical, and Dental Instruments and Supplies median 16.7

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2022 to 2026

Gross margin

52.7%

Operating margin

11.2%

Net margin

8.2%

See a number that looks wrong?